![]() |
|
|
Vol. 63, Issue 4, 925-932, April 2003
Department of Pharmacy, Center of Drug Research, University of
Munich, Munich, Germany (U.G.B.H., A.M.V., V.M.D.); and Department of
Medicine, Division of Cardiology, Emory University, Atlanta, Georgia
(D.S., K.K.G.)
Resveratrol (RV), a polyphenolic stilbene derivative, has been proposed
to exert a plethora of beneficial cardiovascular effects. Of these, in
particular, inhibition of vascular smooth muscle cell (VSMC)
proliferation shows great promise for preventing cardiovascular disease. In the present study, we show that RV leads to a reversible arrest in early S phase of the VSMC cycle, accompanied by an
accumulation of hyperphosphorylated retinoblastoma protein. In contrast
to studies with other cell systems, RV decreases cellular levels of the
cyclin-dependent kinase inhibitors p21Cip1 and
p27Kip1. This is of particular interest
because phosphorylated p53 protein (serine15) is strongly
enhanced by this substance. We further found that RV only slightly
inhibits phosphorylation of Erk 1/2, protein kinase B/Akt, and
p70S6 kinase upon serum stimulation. Thus, inhibition of
these kinases is not likely to contribute to the cell cycle effect of
RV. Importantly, the observed S phase arrest is not linked to an
increase in apoptotic cell death: there was no detectable increase in
apoptotic nuclei and in levels of the proapoptotic protein Bax. This is
the first study elucidating the molecular pathways mediating the
antiproliferative properties of RV in VSMCs.
This article has been cited by other articles:
![]() |
S. A. Gatz, M. Keimling, C. Baumann, T. Dork, K.-M. Debatin, S. Fulda, and L. Wiesmuller Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner Carcinogenesis, March 1, 2008; 29(3): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rayalam, M. A. Della-Fera, J.-Y. Yang, H. J. Park, S. Ambati, and C. A. Baile Resveratrol Potentiates Genistein's Antiadipogenic and Proapoptotic Effects in 3T3-L1 Adipocytes J. Nutr., December 1, 2007; 137(12): 2668 - 2673. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Heiss, Y. D. C. Schilder, and V. M. Dirsch Chronic Treatment with Resveratrol Induces Redox Stress- and Ataxia Telangiectasia-mutated (ATM)-dependent Senescence in p53-positive Cancer Cells J. Biol. Chem., September 14, 2007; 282(37): 26759 - 26766. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ungvari, Z. Orosz, A. Rivera, N. Labinskyy, Z. Xiangmin, S. Olson, A. Podlutsky, and A. Csiszar Resveratrol increases vascular oxidative stress resistance Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2417 - H2424. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sareen, P. R. van Ginkel, J. C. Takach, A. Mohiuddin, S. R. Darjatmoko, D. M. Albert, and A. S. Polans Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3708 - 3716. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lee and S.-K. Moon Resveratrol Inhibits TNF-{alpha}-Induced Proliferation and Matrix Metalloproteinase Expression in Human Vascular Smooth Muscle Cells J. Nutr., December 1, 2005; 135(12): 2767 - 2773. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. G. B. Haider, T. U. Roos, M. I. Kontaridis, B. G. Neel, D. Sorescu, K. K. Griendling, A. M. Vollmar, and V. M. Dirsch Resveratrol Inhibits Angiotensin II- and Epidermal Growth Factor-Mediated Akt Activation: Role of Gab1 and Shp2 Mol. Pharmacol., July 1, 2005; 68(1): 41 - 48. [Abstract] [Full Text] [PDF] |
||||